Search

Displaying results 1661 - 1670 of 5504 in total
  1. Drug

    Levoleucovorin

    go.drugbank.com/drugs/DB11596
    ApprovedInvestigational

    difference in activity, the two commercially available forms have been shown to be pharmacokinetically identical and may be used interchangeably with limited differences in efficacy or side effects (Kovoor et … As methotrexate functions as a DHFR inhibitor to prevent DNA synthesis in rapidly dividing cells, it also prevents the formation of DHF and THF.

  2. Indication

    Heartburn

    go.drugbank.com/conditions/DBCOND0004515
    Drugs: Alginic acid · Almasilate · Aluminium glycinate · Aluminum hydroxide · Belladonna · Bismuth subsalicylate +23 more
  3. Drug

    Apadamtase alfa

    go.drugbank.com/drugs/DB15164
    ApprovedInvestigational

    [A262076] It may be inherited (congenital TTP; cTTP) or acquired due to autoantibodies (immune-mediated TTP; iTTP), although cTTP accounts for <5% of all cases of TTP.

  4. Drug

    Digoxin

    go.drugbank.com/drugs/DB00390
    ApprovedInvestigational

    [A178225] It is a common agent used to manage atrial fibrillation and the symptoms of heart failure.

  5. Drug

    Dactylis glomerata pollen

    go.drugbank.com/drugs/DB10379
    Approved

    Dactylis glomerata pollen is the pollen of the Dactylis glomerata plant. Dactylis glomerata pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS333938, Treatment Set TS128872
  6. Drug

    Dipotassium phosphate

    go.drugbank.com/drugs/DB09414
    ApprovedInvestigational

    Dipotassium phosphate (K2HPO4) is a highly water-soluble salt often used as a fertilizer and food additive as a source of phosphorus and potassium as well as a buffering agent.

    Mixtures: Clinimix E, Clinimix E
  7. Drug

    Setmelanotide

    go.drugbank.com/drugs/DB11700
    ApprovedInvestigational

    [L24474] It is an agonist of the melanocortin 4 receptor. … [L24429] On May 4, 2023, it was approved by Health Canada.[L46327]

  8. Drug

    Lithium citrate

    go.drugbank.com/drugs/DB14507
    ApprovedInvestigational

  9. Drug

    Thrombin

    go.drugbank.com/drugs/DB11300
    ApprovedInvestigational

    It clots the fibrinogen of the blood directly. Failure to clot blood occurs in the rare case where the primary clotting defect is the absence of fibrinogen itself.

    Mixtures: ŞTİ.EL LYO 1 ML TROMBIN ÇÖZELTİSİ VE 1 ML FIBRINOJEN ÇÖZELTİSİ ICEREN IKI BILESENLI FIBRIN YAPISTIRICI, SET 1 (2 İĞNE+2 ENJEKTÖR) VE SET 2 (2 İĞNE +2 ENJEKTÖR+1 ENJEKTÖR KLİPSİ+2 BİRLEŞTİRME PARÇASI+ 4, BERIPLAST-P COMBI SET 1 ML TROMBİN ÇÖZELTİSİ VE 1 ML FİBRİNOJEN ÇÖZELTİSİ İÇEREN FİBRİN YAPIŞTIRICI
  10. Drug

    Albutrepenonacog alfa

    go.drugbank.com/drugs/DB13884
    Approved

    [A32547] It was developed by CSL Behring Canada, Inc and approved by Health Canada on April 26, 2017. It was also approved by FDA and EMA in 2016. … It is currently marketed in the forms of 250, 500, 1000 and 2000 IU/vial.[L2305]